The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 601–700 of 857
Tanaka, T., Koyama, K., Takahashi, N., Morito, K., Ali, H., Azuma, M., Kagawa, K., Kawano, H., Hasi, R. Y., Aihara, M., et al. (2022) · The Journal of Medical Investigation · doi:10.2152/jmi.69.196 · Cited by 8
Design of Anticancer Lysophosphatidic Acid Agonists and Antagonists
Parrill, A. L. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.52 · Cited by 8
Etiology and Pathogenesis of Scleroderma
Varga, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00083-8 · Cited by 9
Sphingosine-1-phosphate metabolism: can its enigmatic lyase promote the autophagy of fibrosis?
Tatler, A. L., & Jenkins, G. R. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207974 · Cited by 9
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
“Subgroup analyses demonstrated a treat-ment effect of 60-mg BMS-986278 with or without LPA is a phospholipid mediator able to activate a growth factor-like response in pulmonary fibroblasts, smooth muscle cells and epithelial cells, all expressing a specific receptor, LPAR 1 [69,70].”
BackgroundWeiss-Tessbach, M., Haider, T., Gowran, A., Schubert, L., Mühlbacher, J., Brankovic, J., Wahrmann, M., Jilma, B., & Boehm, T. (2025) · Inflammation Research · doi:10.1007/s00011-025-02032-5 · Cited by 7
“Nonetheless, LPA is able to induce vascular leakage, plasma exudation and interestingly histamine release from mast cells [ 53 , 54].”
Early Process Development of an LPAR1 Antagonist, GS-2278
Kadunce, N. T., Wagner, A. M., Cottell, J. J., Dao, K., Dixon, D. D., Hodur, B. M., Holte, D., Ischay, M. A., Kang, J., Kim, S., et al. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00369 · Cited by 7
Zong, C., Zhang, X., Xie, Y., & Cheng, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3353 · Cited by 7
Etiology and Pathogenesis of Scleroderma
Varga, J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00083-9 · Cited by 8
Wen, J., Lin, X., Gao, W., Qu, B., Zuo, Y., Liu, R., & Yu, M. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0120 · Cited by 7
Naruse, T., Otake, H., & Takahashi, T. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.05.003 · Cited by 7
New renal drug development to face chronic renal disease
Moll, S., Meier, M., Formentini, I., Pomposiello, S. I., & Prunotto, M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.956075 · Cited by 7
“In addition, the LPA receptor 1 (LPA1) was demonstrated to be highly expressed on lung fibroblasts isolated in BAL fluid from patients with IPF [56].”
BackgroundJu, Y., Huang, L., Wang, S., & Zhao, S. (2020) · Analytical Cellular Pathology · doi:10.1155/2020/6128341 · Cited by 8
“LPAR1 contributes to fibrosis and cell migration in response to injury [49, 50].”
BackgroundMolecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease
Newton, C. A., & Herzog, E. L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.011 · Cited by 7
Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546
Ma, B., Zhang, L., Sun, L., Xin, Z., Kumaravel, G., Marcotte, D. J., Chodaparambil, J. V., Wang, Q., Wehr, A. Y., Jing, J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00211 · Cited by 7
Allergic to Autotaxin. A New Role for Lysophospholipase D and Lysophosphatidic Acid in Asthma?
Georas, S. N. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1597ed · Cited by 7
“The first hypothesis-free genome-wide association studies (GWAS) have revealed HHIP, CHRNA3/5, and FAM13A loci to be associated with COPD defined as airway obstruction (FEV1/FVC , 70%) (6–8) and BICD110 (9) loci to be associated with the emphysema phenotype that is not captured by lung function alone, but using radiog…”
BackgroundInfluentialBouffette, S., Soret, P., Cole, A. R., Nony, E., Hilaire, P. B. S., Leclerc, G., Alaoui, L., Aussy, A., Wehrle, I., Gall, A. L., et al. (2025) · FEBS Journal · doi:10.1111/febs.70177 · Cited by 6
“LPA signaling through its receptor LPA1 mediates fibroblast recruitment and vascular leakage [29].”
Lysophosphatidic Acid (LPA) Receptor Signaling
Mirendil, H., Lin, M., & Chun, J. J. M. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch1 · Cited by 6
Self-citationPathophysiology of Fibrosis in Systemic Sclerosis
Trojanowska, M., & Varga, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_18 · Cited by 6
Chen, J., Zou, P., Li, Q., Gong, C., Fang, Z., Lin, B., Lang, J., & Chen, M. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119026 · Cited by 6
Ma, D., Zhao, B. T., Yue, L., Li, S., Wei, X., Jiang, N., Zang, L., Lei, H., & Zhai, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03173 · Cited by 6
Roles of eicosanoids in pulmonary fibrosis
Oga, T., Handa, T., Mishima, M., Chin, K., & Narumiya, S. (2013) · Inflammation and Regeneration · doi:10.2492/inflammregen.33.109 · Cited by 6
Xie, Y., Wang, Y., Zong, C., & Cheng, J. (2014) · Pharmacology · doi:10.1159/000360638 · Cited by 6
Boleto, G., Avouac, J., & Allanore, Y. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211066686 · Cited by 6
“Hit” to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors
Stylianaki, E.-A., Magkrioti, C., Ladopoulou, E. M., Papavasileiou, K. D., Lagarias, P. I., Melagraki, G., Samiotaki, M. K., Panayotou, G., Dedos, S., Afantitis, A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115130 · Cited by 6
Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors
Jia, F., Lei, H., Chen, Y., Li, T., Xing, L., Cao, Z., & Zhai, X. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115795 · Cited by 7
Imaging Autotaxin In Vivo with 18F-Labeled Positron Emission Tomography Ligands
Deng, X., Salgado-Polo, F., Shao, T., Xiao, Z., Van, R. S., Chen, J., Rong, J., Haider, A., Shao, Y., Josephson, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00913 · Cited by 6
Imani, J., Bodine, S. P., Lamattina, A. M., Ma, D. D., Shrestha, S., Maynard, D., Bishop, K. S., Nwokeji, A., Malicdan, M. C. V., Testa, L. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02083-w · Cited by 6
“In light of the deleterious impact of unchecked fibroblast migration on tissue remodeling [40], our observations strongly support the prominent role of HPSLF in promoting lung Fig.”
ResultFirst-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor
Im, D. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0600-2 · Cited by 6
Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
Lederer, D. J. (2013) · European Respiratory Journal · doi:10.1183/09031936.00092713 · Cited by 7
Emerging concepts and novel mechanisms in organ fibrosis
Ruiz‐Villalba, A., & Pardo–Saganta, A. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00446-7 · Cited by 7
Lysophosphatidic Acid Regulates Endothelial Barrier Integrity
Zhao, J., Taleb, S. J., Wang, H., & Zhao, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_16 · Cited by 6
Liu, M., Cheng, Z. J., Xue, M., Lin, R., Zhang, T., & Sun, B. (2023) · Precision Medical Sciences · doi:10.1002/prm2.12106 · Cited by 5
White, M. J. V., Raczy, M. M., Budina, E., Yuba, E., Solanki, A., Shim, H.-N., Zhang, Z. J., Gray, L. T., Cao, S., Alpar, A. T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94073-3 · Cited by 5
Guo, L., Xia, Z., Wang, J., Xiao-ling, Y., Wu, C., Luo, Q., & Zhao, C. (2025) · Open Research (University of Surrey) · doi:10.1002/viw.20240127 · Cited by 5
An ATX-LPA6-Gα13-ROCK axis shapes and maintains caudal vein plexus in zebrafish
Okasato, R., Kano, K., Kise, R., Inoue, A., Fukuhara, S., & Aoki, J. (2021) · iScience · doi:10.1016/j.isci.2021.103254 · Cited by 5
GPR176 promotes fibroblast-to-myofibroblast transition in organ fibrosis progression
Okamoto, Y., Kitakaze, K., Takenouchi, Y., Matsui, R., Koga, D., Miyashima, R., Ishimaru, H., & Tsuboi, K. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119798 · Cited by 6
A novel stroke locus identified in a northern Sweden pedigree
Janunger, T., Nilsson-Ardnor, S., Wiklund, P.-G., Lindgren, P., Escher, S. A., Lackovic, K., Nilsson, A. K., Stegmayr, B. G., Asplund, K., & Holmberg, D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34b1d · Cited by 5
Caveolin-1 stops profibrogenic signaling?
Kim, H. P., & Choi, A. M. K. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00073.2008 · Cited by 5
“It is now believed that lung fibrosis is mainly an epithelial/fibroblasts-linked disease in which stimuli first disrupt the homeostasis of parenchymal epithelial cells, resulting in epithelial cell activation (12, 17) and recruitment of immune cells ( 15 ).”
BackgroundInfluentialSacchetti, C., & Bottini, N. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0655-7 · Cited by 8
Dipyridamole reduces penile apoptosis in a rat model of post-prostatectomy erectile dysfunction
Kutlu, Ö., Karagüzel, E., Okatan, A. E., Menteşe, A., Yuluğ, E., Kazaz, İ. O., Kutlu, S., Dil, E., Eren, H., & Alver, A. (2017) · International braz j urol · doi:10.1590/s1677-5538.ibju.2017.0023 · Cited by 5
“Adenosine induced vasodilatation is mediated by increased intracellular cyclic adenosine mono phosphate (cAMP) levels in vascular smooth muscle cells via A2 receptor signaling (42, 43).”
BackgroundDuflot, T., Tu, L., Leuillier, M., Messaoudi, H., Groussard, D., Feugray, G., Azhar, S., Thuillet, R., Bauer, F., Humbert, M. J. C., et al. (2021) · Metabolites · doi:10.3390/metabo11110784 · Cited by 5
Sun, K., Chen, R., Li, J., & Luo, Z. (2022) · Hereditas · doi:10.1186/s41065-022-00229-w · Cited by 6
Strategy for the Identification of GPR23/LPA 4 Receptor Agonists and Inverse Agonists
Wong, S.-H., Mallari, R., Graham, M., Atangan, L. I., Lu, S.-C., Zhao, X., Gu, W., & Lee, P. H. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0261 · Cited by 5
Asano, Y., & Distler, J. H. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_19 · Cited by 5
Matas-Rico, E., Frijlink, E., Àvila, I. V. D. H., Menegakis, A., van Zon, M., Morris, A. J., Köster, J., Salgado-Polo, F., de Kivit, S., Lança, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.26.966291 · Cited by 5
Yue, R., Yang, T., Niu, D., Zeng, Z., Wang, X., Pan, L., & Yao, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318246 · Cited by 4
“…(PC), LPI, lysophosphatidylethanolamine (LysoPE), phosphatidylethanolamine (PE), and lysophosphatidylcholine (LysoPC) [30], which are the crucial differential metabolites in the progression of PF. LysoPC induces the PF by mediating vascular leakage and fibroblast migration and proliferation [31].”
de Soto, J. G., Castro‐Mosquera, M., Pouso-Diz, J. M., Cabrera, A. F., Rodríguez‐Arrizabalaga, M., Debasa‐Mouce, M., Camino-Castiñeiras, J., Pereiro, A. M. M., Aramburu-Núñez, M., Romaus‐Sanjurjo, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157068 · Cited by 4
“It has also been implicated in pathological processes, such as different types of cancer [33–41], rheumatologic diseases [42,43], pulmonary fibrosis [44,45], psychiatric disorders, and neurological disorders [23,46–49].”
Lysophosphatidic acid stimulates pericyte migration via LPA receptor 1
Yonezu, Y., Tanabe, S., Misawa, H., & Muramatsu, R. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.06.016 · Cited by 4
The Effect of Anti-Autotaxin Aptamers on the Development of Proliferative Vitreoretinopathy
Hanazaki, H., Yokota, H., Yamagami, S., Nakamura, Y., & Nagaoka, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115926 · Cited by 4
Zeng, Y., Zhang, R., Yue, J., Li, D., Chen, L., Dong, G., Zhang, R., Niu, Y., Chen, W., & Chen, S. (2024) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2024.503807 · Cited by 4
Giuliani, M., Rizzi, A., Pagano, M., Raveglia, L. F., Saccani, F., Lascia, M. R. D., Interlandi, M., Nardella, T. S., Marchini, G., Murgo, A., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00559 · Cited by 6
Dynamic actin remodeling in response to lysophosphatidic acid
Mir, S. S., Bhat, H. F., & Bhat, Z. F. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1696230 · Cited by 4
Zhang, J., Vardy, E., Muise, E., Wang, T.-M., Visconti, R., Vadlamudi, A., Pinto, S., & Peier, A. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000103 · Cited by 1
“Lysophosphatidic acid receptor 1 has been found linking pulmonary fibrosis to lung injury (Tager et al., 2008).”
BackgroundSant’Anna, J. F., Baldez, V., Garrão, N. R., Lemos, T., Diaz, B. L., & Einicker‐Lamas, M. (2021) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-021-00800-5 · Cited by 4
Córdova-Casanova, A., Cruz-Soca, M., Gallardo, F. S., Faundez-Contreras, J., Bock-Pereda, A., Chun, J. J. M., Vio, C. P., Casar, J. C., & Brandan, E. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.05.001 · Cited by 4
Self-citationSteiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Application of Organometallic Catalysts in API Synthesis
Basu, D., Achanta, S., Kumar, N. U., Budhdev, R. R., & Bandichhor, R. (2019) · Topics in organometallic chemistry · doi:10.1007/3418_2019_31 · Cited by 4
Morales, M. M., Pedowitz, N. J., & Pratt, M. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100800 · Cited by 4
“Mouse embryonic fibroblast cell line NIH3T3 (American TypeCultureCollection [ATCC])was propagated inDulbecco’s modified Eagle’s medium (DMEM) (Genesee Scientific) supplemented with 10% fetal calf serum (FCS) (Atlanta Biologics).”
MethodInfluentialHong, Z. (2012) · The Journal of Third World Studies · Cited by 4
Hypoxia Promotes Invadosome Formation by Lung Fibroblasts
Lebel, M., Cliché, D. O., Charbonneau, M., Brochu‐Gaudreau, K., Adam, D., Brochiero, E., Dubois, C. M., & Cantin, A. M. (2024) · Cells · doi:10.3390/cells13131152 · Cited by 4
“LPA 1 is the main LPA receptor expressed by pulmonary fibroblasts, and the LPA-LPA 1 axis was shown to be involved in pulmonary fibroblast migration and resistance to apoptosis [46].”
BackgroundLipid Mediators in Inflammation
Narumiya, S., Yokomizo, T., & Aoki, J. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch26 · Cited by 4
Delogu, G., Sali, M., Rocca, S., Quintiliani, G., Santucci, M. B., Greco, E., Cabibbo, A., Mariani, F., Colizzi, V., Fadda, G., et al. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.05.014 · Cited by 4
Molecular Regulation of Lysophosphatidic Acid Receptor 1 Maturation and Desensitization
Zhao, J., Stephens, T., & Zhao, Y. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-00999-6 · Cited by 4
Generation of a novel lung fibrosis model using precision-cut lung slices from transgenic TGFβ1 mice
Liu, Y., Papagianis, P. C., de Kuijper, Z., Chitty, J. G., Thomas, B. J., Borghuis, T., Jongman, R. M., Pillay, J., Richards, E. A., Melgert, B. N., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00015.2025 · Cited by 3
Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis
Han, X., Wang, X., Huang, J., & Yang, J. Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152811 · Cited by 3
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis
Poon, M. M., Lorrain, K. I., Broadhead, A. R., Stebbins, K. J., Bagnol, D., Edu, G. C., Joseph, G. U., Baccei, C. S., Roppe, J. R., Schrader, T. O., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03340-4 · Cited by 4
“Both phenomena have been shown to be inhibited by other LPAR1 small molecule antagonists or in LPAR1 knockout mice [4, 5].”
InfluentialLi, J., Chen, M., Lu, L., Wang, Y., Wu, W., & Feng, Y. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.08.012 · Cited by 3
Integration of cAMP and TRPV4 Signaling to Optimize Collagen Remodeling for Management of Fibrosis
Raimo, C. D., & McCulloch, C. (2025) · Cells · doi:10.3390/cells15010056 · Cited by 3
Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight
Takeda, A., & Ishii, Y. (2017) · InTech eBooks · doi:10.5772/intechopen.70864 · Cited by 3
Choi, W.-I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00205 · Cited by 3
“Researchers have demonstrated an important role of LPA signaling through one of the receptors, LPA1, in animal models of fibrosis in several organs, including the lungs [65,66].”
BackgroundDecrease in serum levels of autotaxin in COVID-19 patients
Shimura, T., Kurano, M., Okamoto, K., Jubishi, D., Hashimoto, H., Kano, K., Igarashi, K., Shimamoto, S., Aoki, J., Moriya, K., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2143554 · Cited by 3
“In addition, accumulating data suggest that lysophospholipid mediators, such as LPA, are also generated during inflammatory and immune responses and regulate the progression of disease states both positively and negatively, depending on each specific G protein-coupled receptor [10].”
Громова, О. А., & Torshin, I. Y. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-3-128-138 · Cited by 3
Li, H., Huang, Z., Yang, C., Han, D., Wang, X., Qiu, X., Zhang, Z., & Chen, X. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26685 · Cited by 3
Ruzza, C., Argentieri, M., Ferrari, F., Armani, E., Trevisani, M., Marchini, G., & Calò, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1267414 · Cited by 3
ERS International Congress 2023: highlights from the Basic and Translational Sciences Assembly
Reddy, K. V. V. S. N., Bizymi, N., Schweikert, A., Ananth, S., Lim, C. X., Lodge, K. M., Joannes, A., Ubags, N. D. J., van der Does, A. M., Cloonan, S. M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00875-2023 · Cited by 3
“Treating these fibrotic organoids with HL001, a lysophosphatidic acid 1 (LPA1) antagonist [120], showed a restorative effect with a decrease in fibrosis and an increase in AT2 cell marker.”
BackgroundLin, F., Lin, K., Li, D., Kong, W., Zhuang, J., He, W., Wei, X., Xiao, T., Zu, H., Zhang, Z., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03696-9 · Cited by 3
Lysophosphatidic Acid Receptors in Cancer
Mukherjee, A., Wu, J., Gong, Y., & Fang, X. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch31 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Biomarkers in Idiopathic Pulmonary Fibrosis: A RAGE-ing Bull in the Arena
Τzouvelekis, Α., Bouros, D. E., & Aidinis, V. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201701-024ed · Cited by 3
Fibrotic Signaling in the Lung
Dutta, J. A., Bahudhanapati, H., Tan, J., Goldblum, A., & Kass, D. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_4 · Cited by 2
Varga, J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_21 · Cited by 2
“A recent study indicates that LPA induces av b 6 integrin-mediated activation of latent TGF- b in epithelial cells, contributing to sustained autocrine and paracrine TGFb signaling [ 52 ] .”
BackgroundKim, M., La, M. T., Shin, Y. A., Yang, S., Kim, E. J., Lee, S., Jung, H. Y., Na, S., Seo, W., Lee, B., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108426 · Cited by 2
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 7
“144,150 An LPAR 1/3 inhibitor was also shown to reduce the development of radiation fi brosis in mice.”
Zhao, B. T., Xu, S., Wei, X., Li, Y., Qu, S., Lei, H., & Zhai, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118011 · Cited by 2
Tirelli, C., Muscato, G., Alaimo, C., Leo, I. D., Mirijaj, S., Pennisi, F., Vancheri, C., & Mondoni, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114172 · Cited by 2
Translational research on autotaxin-LPA-LPA receptors and drug discovery
Im, D. (2015) · Clinical Lipidology · doi:10.2217/clp.15.4 · Cited by 2
Zhao, Y. (2012) · Journal of Allergy & Therapy · doi:10.4172/2155-6121.s4-005 · Cited by 2
“LPA1 deficient mice reduce intratracheal LPS [3] and bleomycin [19]-induced acute lung injuries.”
BackgroundThe Role of Lysophospholipids in Immune Cell Trafficking and Inflammation
Miyasaka, M., Takeda, A., Hata, E., Sasaki, N., Umemoto, E., & Jalkanen, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-56068-5_35 · Cited by 3
Kobayashi, Y., Uneuchi, F., Naruse, T., Matsuda, D., Okumura-Kitajima, L., Kajiyama, H., Wada, R., Yonemoto, Y., Nakano, K., Toki, H., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115749 · Cited by 2
Deng, X., Liu, J., Zhou, J., Shi, Y., Song, S., Chen, J., Li, Y., Yu, B., Liang, S. H., & Zhu, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00571 · Cited by 2
Generation of New Knock-Out Mouse Strains of Lysophosphatidic Acid Receptor 1
Antonopoulou, G., Magkrioti, C., Chatzidaki, I., Nastos, D., Grammenoudi, S., Bozonelos, K., & Aidinis, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062811 · Cited by 2
“Regarding the roles of LPAR1 outside the nervous system, it has been shown that the levels of this receptor are increased in lung inflammatory disorders, such as asthma [13] and IPF [14].”
Targeting E3 ubiquitin ligases: a new frontier in idiopathic pulmonary fibrosis treatment
Zhang, K., Yuan, H., & Shi, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618424 · Cited by 6
Clinical Introduction of Lysophosphatidic Acid (LPA) and Autotaxin Assays
Yatomi, Y., Igarashi, K., Nakamura, K., Ohkawa, R., Masuda, A., Suzuki, A., Kishimoto, T., Ikeda, H., & Aoki, J. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch33 · Cited by 2
Current and Future Therapies for Idiopathic Pulmonary Fibrosis
Spagnolo, P., Bonella, F., Vašáková, M., Kreuter, M., & Maher, T. M. (2015) · Pulmonary Therapy · doi:10.1007/s41030-015-0009-4 · Cited by 2
Fibrosis and Immune Dysregulation in Systemic Sclerosis
Argobi, Y., & Smith, G. P. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_2 · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“LPA also increases vascular permeability, promoting the fibrotic process through the enhancement of blood coagulation and fibrin deposition, and it is risen in the BALF of patients with IPF [61].”
BackgroundWang, H., Chen, Y., Qi, X., Zhang, H., Zhai, X., & Sun, L. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.114606 · Cited by 2
Ahn, J. H., Kim, J.-H., Lee, K. C., Park, J. A., Kim, J. Y., Lee, Y., & Lee, Y. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00632 · Cited by 2
Fibroblasts as matrix modulating cells in asthma and COPD
Nihlberg, K. (2009) · Lund University Publications (Lund University) · Cited by 2
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.